Loading
companiesCompany
Faron Pharmaceuticals
Faron Pharmaceuticals is a Finnish biotech whose antibody bexmarilimab re-programmes immunosuppressive macrophages, with early activity in myelodysplastic syndromes and leukaemia.
Also called: FaronAIM:FARN
Overview
Faron Pharmaceuticals, based in Turku and listed in London and Helsinki, develops immunotherapies that act on the myeloid arm of the immune system. Its lead candidate, bexmarilimab (FP-1305), binds Clever-1 on tumour-associated macrophages and converts them from an immunosuppressive to an immune-activating state. The BEXMAB study combines it with azacitidine in myelodysplastic syndromes and acute myeloid leukaemia; earlier MATINS trials tested it in solid tumours.
Headquarters
Turku, FI
Scorecard
All companies#418of 1244 companies, score 8
- phase 1/2 +1
- modalities +2
- registry trials +5
0 approved, 0 in phase 3, 1 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Biotech · AIM:FARN
Stage
Public
Website
Phase 2Monoclonal antibody
Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms.
Similar pages
drugs
Phase 2Monoclonal antibody